Real-time monitoring of tumor progression and drug responses in a preclinical mouse model of prostate cancer
Metrics: PDF 1331 views | HTML 2746 views | ?
Peng Xu1,2,*, Naijin Xu2,*, Kai Guo1,2,*, Abai Xu1, Fumiaki Takenaka3, Eiji Matsuura3, Chunxiao Liu1, Hiromi Kumon4, Peng Huang1,2,3
1Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
2Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
3Okayama Medical Innovation Center, Okayama University, Okayama, Japan
4Innovation Center Okayama for Nanobio-Targeted Therapy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
*These authors contributed to the work equally and should be regarded as co-first authors
Peng Huang, email: [email protected]
Keywords: prostate cancer, bioluminescence imaging, prostate specific antigen, immunotherapy, preclinical model
Received: January 09, 2016 Accepted: March 31, 2016 Published: April 20, 2016
Monitoring disease progression through imaging is playing an increasingly important role in the treatment of prostate cancer. Here, we report that primary mouse prostate cancer cell lines stably expressing luciferase and tumor biomarkers can be monitored through bioluminescence imaging along with assays of serum biomarkers and immune function. Tumorigenesis in immunocompetent C57BL/6 mice can be monitored in by collecting samples from the dorsal flank, dorsolateral prostate, and tail vein to obtain real-time subcutaneous, orthotopic, and metastasis indicators, respectively. We used this technique to confirm the therapeutic effect of immune checkpoint blockade. Our findings suggest the presented indicators are ideally suited for real-time tracking of drug responses, tumor progression and immune function.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.